7 results
To demonstrate that SCS is capable of treating otherwise refractory neuropathic pain after chemotherapy / radiotherapy.
Primary objectives: - Clinical: To assess the efficacy of MPDL3280A pre-cystectomy with respect to pCRR in patients with T2-T4aN0M0 transitional cell carcinoma of the bladder- Biological: To assess the effect of 2 x 3 weekly cycles of MPDL3280A pre-…
To validate the results from two RCTs that SCS is indeed capable of treating otherwise refractory diabetic neuropathic pain, and to evaluate the effects of burst stimulation settings in this patient group.
The objective of this study is to assess the feasibility of SCS using the Wavewriter Alpha for control of treatment resistant endometriosis-related pain symptoms
To evaluate and quantify the various clinical effects of closed-loop SCS versus open-loop SCS on the underlying pathophysiological effects in CRPS.
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…
Objectives - Core StudyPrimary Objectives• To evaluate the effects of oral ALZ-801 in subjects with Early AD who have the APOE4/4 or APOE3/4 genotype, on the plasma biomarkers of core AD pathology and brain volumes* Primary Plasma Biomarker Outcome…